Moderna, Inc. (ETR:0QF)
23.81
-2.64 (-9.97%)
At close: Aug 1, 2025, 5:30 PM CET
Moderna Revenue
Moderna had revenue of $142.00M USD in the quarter ending June 30, 2025, a decrease of -41.08%. This brings the company's revenue in the last twelve months to $3.08B, down -39.05% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.08B
Revenue Growth
-39.05%
P/S Ratio
3.53
Revenue / Employee
$530.69K
Employees
5,800
Market Cap
9.25B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
Moderna News
- 1 day ago - UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech - Wallstreet:Online
- 1 day ago - UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech - Accesswire
- 1 day ago - Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters
- 1 day ago - Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
- 1 day ago - Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
- 1 day ago - Moderna braces for deep Q2 loss as vaccine demand wanes - Seeking Alpha
- 1 day ago - Moderna's Earnings: A Preview - Benzinga
- 1 day ago - Moderna gets EU nod for updated COVID-19 vaccine - Seeking Alpha